Pharmacodynamic and pharmacokinetic properties of the fosfomycin along with the spectrum of its antimicrobial activity are discussed in this article with regard to the available evidence database. Fosfomycin is supplied to the market in 2 forms (fosfomycin trometamol) parenteral (fosfomycin sodium), which show the substantial differences in pharmacological features and are indicated in different conditions. Fosfomycin trometamol mainly in patients with acute cystitis. Nevertheless many studies and two metaanalysis failed to show its superiority in comparison with cephalosporins, fluoroquinolones and aminoglycosides; the only advantage was a more comfortable form of usage. It was denoted, that fosfomycin therapy was safe during pregnancy and in pediatric patients.

In the conclusion of the article some clinical situation are described in details, from which it becomes clear, when the use of the fosfomycin is expedient, and when not.